Peritoneal dialysis in diabetic end-stage renal disease

  • Ramesh Khanna

Abstract

The management of the diabetic patients with end-stage renal disease (ESRD) has undergone significant change over the past 20 years. In countries with adequate socioeconomic conditions, even diabetics with extensive comorbid diseases denied renal transplantation easily get accepted for chronic dialysis despite the inevitable poor long-term prognosis [1–4]. As a result, diabetes has become the most prevalent cause of ESRD in the USA; on average, about one-third of the new dialysis patients have diabetes as the cause of renal disease [5]. Renal transplantation is the generally preferred treatment for diabetic patients with end-stage renal failure because it leads to better quality of life than any form of dialysis [6]. Although improved compared to a decade ago, the outcome of dialysis therapies (hemodialysis or peritoneal dialysis) for diabetics is still disappointing compared to renal transplantation and dialysis for non-diabetics; nearly half the diabetic patients, who begin dialysis do not survive beyond two years [7] and less than one in five diabetic patients undergoing maintenance dialysis is capable of any activity beyond personal care.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Friedman EA. Clinical imperatives in diabetic nephropathy. Kidney Int 1982; 23 (suppl): S16–9.Google Scholar
  2. 2.
    Friedman EA. Overview of diabetic nephropathy. In: Keen H, Legrain M (eds), Prevention and Treatment of Diabetic Nephropathy. MTP, Lancaster 1983; pp 3–19.Google Scholar
  3. 3.
    Friedman EA. Clinical strategy in diabetic nephropathy. In: Friedman E, L’Esperance F (eds), Diabetic Renal-Retinal Syndrome 3. Grune and Stratton, New York 1986; pp 331–7.Google Scholar
  4. 4.
    Legrain M. Diabetics with end-stage renal disease: the best buy. Editorial. Diabetic Nephropathy 2: 1–3.Google Scholar
  5. 5.
    Markell MS, Friedman EA. Care of the diabetic patient with end-stage renal disease. Semin Nephrology 1990; 10: 274–86.Google Scholar
  6. 6.
    Friedman EA. How can the case of diabetic ESRD patients be improved? Seminars in Dialysis 1991; 4: 13–4.CrossRefGoogle Scholar
  7. 7.
    U.S. Renal Data Systems. USRDS 1989 Annual Data Report. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, August 1989.Google Scholar
  8. 8.
    Katirtzoglou A, Izatt S, Oreopoulos DG. Chronic peritoneal dialysis in diabetics with end-stage renal failure. In: Friedman EA (ed), Diabetic Renal-Retinal Syndrome. Grune &Stratton, Orlando 1982; pp 317–32.Google Scholar
  9. 9.
    Blumenkrantz MJ, Shapiro DJ, Minura N, Oreopoulos DG, Friedler RM, Levin S, Tenckhoff H, Coburn JW. Maintenance peritoneal dialysis as an alternative in the patients with diabetes mellitus and end-stage uremia. Kidney International 1974; 6 (suppl 1): S108.Google Scholar
  10. 10.
    Quelhorst E, Schuenemann B, Mietzsch G, Jacob I. Hemo and peritoneal dialysis treatment of patient with diabetic nephropathy. A comparative study. Proceedings of the European Dialysis and Transplant Association 1978; 15: 205.PubMedGoogle Scholar
  11. 11.
    Mion C, Slingeneyer A, Salem JL, Oules R, Mirouze J. Home peritoneal dialysis in end-stage diabetic nephropathy. Journal of Dialysis 1978; 2: 426–7.Google Scholar
  12. 12.
    Warden GS, Maxwell JG, Stephen RL. The use of reciprocating peritoneal dialysis with a subcutaneous peritoneal dialysis in end-stage renal failure in diabetes mellitus. Journal of Surgical Research 1978; 24: 495–500.PubMedCrossRefGoogle Scholar
  13. 13.
    Amair P, Khanna R, Leibel B, Peirratos A, Vas S, Meema G, Chisholm L, Vas M, Zingg W, Digenis G, Oreopoulos DG. Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease. N Eng J of Med 1982; 306: 625–30.CrossRefGoogle Scholar
  14. 14.
    Legrain M, Rottembourg J, Bentchikou A, Poignet JL, Issad B, Barthelemy A, Strippoli P. Dialysis treatment of insulin dependent diabetic patients. A ten year experience. Clinical Nephrology 1984; 21: 72–81.PubMedGoogle Scholar
  15. 15.
    Lameire N, Dhaene M, Matthys E, de Paepe M,Vereerstraeten P, Drawtwa M, Ringoir S. Experience with CAPD in diabetic patients. In: Keen H, Legrain M (eds), Prevention and Treatment of Diabetic Nephropathy. MTP Ltd, Lancaster 1983; pp 289–97.Google Scholar
  16. 16.
    Polla-Imhoof B, Pirson Y, Lafontaine JJ, Vandenbrouche JM, Cosyns JP, Squifflet JP, Alexandre G, van Ypersele de Strihou C. Resultats de Thémodialyse chronique et de la transplantation rénale dans le traitement de l’urémie terminate du diabétique. Néphrologie 1982; 3: 80–4.PubMedGoogle Scholar
  17. 17.
    Thompson NW, Simpson RW, Hooke D, Atkins RC. Peritoneal dialysis in the treatment of diabetic end-stage renal failure. In: Atkins R, Thomson NM, Farell PC (eds), Peritoneal Dialysis. Churchill Livingstone, New York 1981; pp 345–55.Google Scholar
  18. 18.
    Khanna R, Wu G, Chisholm L, Oreopoulos DG. pdate: further experience with CAPD in diabetics with end-stage disease. Diabetic Nephropathy 1983; 2: 8–12.Google Scholar
  19. 19.
    Khanna R, Wu G, Prowant B, Jastrzebska J, Nolph KD, Oreopoulos DG. Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease: a combined experience of two North American centers. In: Friedman E, l’Esperance F (eds), Diabetic Renal Retinal Syndrome 3. Grune and Stratton, New York 1986; pp 363–81.Google Scholar
  20. 20.
    Rottembourg J. Le traitement de l’insuffisance rénale du diabétique. La Presse Med 1987; 46: 437–40.Google Scholar
  21. 21.
    Shapiro FL. Haemodialysis in diabetic patients. In: Keen H, Legrain M (eds), Prevention and treatment of Diabetic Nephropathy. MTP Ltd, Lancaster 1983; pp 247–359.Google Scholar
  22. 22.
    Khanna R, Oreopoulos DG. Continuous ambulatory peritoneal dialysis in diabetics. In: Brenner BM, Stein JH (eds), Diabetes Mellitus. Churchill Livingstone, New York 1989; pp 185–202.Google Scholar
  23. 23.
    Mauer SM, Morgensen CE, Kjellstrand CM. Diabetic nephropathy. In: Schrier RW, Gottschalk CW (eds), Diseases of the Kidney. Little, Brown and Company, Boston 1993; pp 2153–88.Google Scholar
  24. 24.
    Narins RG, Krishna GG, Kopyt NP. Fluid-electrolyte and acid-base disorders complicating diabetes mellitus. In: Schrier RW, Gottschalk GW (eds), Diseases of the Kidney. Little, Brown and Company, Boston 1993; pp 2563–97.Google Scholar
  25. 25.
    Tenckhoff H, Schechter H. A bacteriologically safe peritoneal access device. Transactions of the American Society of Artificial Internal Organs 1968; 14: 181.Google Scholar
  26. 26.
    Khanna R, Twardowski ZJ. Peritoneal access. In: Nolph KD (ed), Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht 1989; pp 319–43.Google Scholar
  27. 27.
    Lindblad AS, Novak JW, Nolph KD, Stablein DM, Cutler SJ, Steinberg SM, Vena DA. In: Continuous Ambulatory Peritoneal Dialysis in the USA. Kluwer Academic Publishers, Dordrecht 1989; pp 63–74.CrossRefGoogle Scholar
  28. 28.
    Twardowski ZJ, Nolph KD, Khanna R, Gluck Z, Prowant BF, Ryan LP. Daily clearances with continuous ambulatory peritoneal dialysis and nightly peritoneal dialysis. Trans Am Soc Artif Intern Organs 1986; 12: 575–80.CrossRefGoogle Scholar
  29. 29.
    Khanna R, Twardowski ZJ, Gluck Z, Ryan LP, Nolph KD. Is nightly peritoneal dialysis (NPD) an effective peritoneal dialysis schedule? (Abstracts) American Society of Nephrology-Kidney Int 1986; 29: 233.Google Scholar
  30. 30.
    Nolph KD, Twardowski ZJ, Khanna R. Clinical pathology conference: peritoneal dialysis. Trans Am Soc Artif Intern Organs 1986; 32: 11–16.Google Scholar
  31. 31.
    Scribner BH. Forward to second edition. In: Nolph KD (ed), Peritoneal Dialysis, second edition. Martinus Nijhoff Publishers, Boston/Dordrecht/ Lancaster 1985; pp XI–XII.Google Scholar
  32. 32.
    Twardowski ZJ, Khanna R, Nolph KD,Scalamogna A, Metzler MH, Schneider TW, Prowant BF, Ryan LP. Intraabdominal pressure during natural activities in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1986; 44: 129–35.PubMedCrossRefGoogle Scholar
  33. 33.
    Twardowski ZJ. New approaches to intermittent peritoneal dialysis therapies. In: Nolph KD (ed), Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht 1988; pp 133–51.Google Scholar
  34. 34.
    Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Frock J, Dobbie J, Serkes K, Kenley R, Witsoe D, Barber J. Tidal peritoneal dialysis. Proceedings of the IVth Congress of the International Society for Peritoneal Dialysis, Venice, Italy, June 29-July 2, 1987.Google Scholar
  35. 35.
    Diaz-Buxo JA. Continuous cyclic peritoneal dialysis. In: Nolph KD (ed), Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht 1989; pp 169–83.CrossRefGoogle Scholar
  36. 36.
    Perras ST, Zappacosta AR. Reduction of peritonitis with patients education and Travenol CAPD germicidal exchange system. American Nephrology Nurses Association 1986; 13: 219.Google Scholar
  37. 37.
    Hamilton RW. The sterile connection device: a review of its development and status report — 1986. In: Khanna R, Nolph KD, Prowant BF et al. (eds), Advances in Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis Bulletin Inc, Toronto 1986; pp 186–9.Google Scholar
  38. 38.
    Fenton SSA, Wu G, Bowman C, Cattran DC, Manuel A, Khanna R, Vas S, Oreopoulos DG. The reduction in the peritonitis rate among high-risk CAPD patients with the use of the Oreopoulos-Zellerman connector. Transactions of the American Society for Artificial Internal Organs 1985; 31: 560.PubMedGoogle Scholar
  39. 39.
    Buoncristiani U, Quintaliani G, Cozzari M, Carobia C. Current status of the Y-set. In: Khanna R et al. (eds), Advances in Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis Bulletin Inc, Toronto 1986; pp 165–71.Google Scholar
  40. 40.
    Flynn CT. The diabetics on CAPD. In: Friedman EA (ed), Diabetic Renal-Retinal Syndrome. Grune &Stratton, Orlando 1982; pp 321–30.Google Scholar
  41. 41.
    Keshaviah P. Adequacy of CAPD: a quantitative approach. Kidney Int 1992; 42 (suppl 38): S160–4.Google Scholar
  42. 42.
    Keshaviah P, Nolph KD. The peak concentration hypothesis: a urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Perit Dial Int 1989; 9: 257–60.PubMedGoogle Scholar
  43. 43.
    Keshaviah P, Nolph KD, Prowant BF. Defining adequacy of CAPD with urea kinetics. Adv Perit Dial 1990; 6: 173–7.PubMedGoogle Scholar
  44. 44.
    Lindholm B, Bergström J. Nutritional management of patients undergoing peritoneal dialysis. In: Nolph KD (ed), Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht 1988; pp 230–60.Google Scholar
  45. 45.
    Stout RW. Diabetes and atherosclerosis — the role of insulin. Diabetologia 1979; 16: 141.PubMedCrossRefGoogle Scholar
  46. 46.
    Zavaroni A, Bonora E, Pagliara M, Dall’Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnudi L, Passeri M, Reaven G. Risk factor for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. New England Journal of Medicine 1989; 320: 702–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Bazzato G, Coli U, Landini S. Xylitol and low doses of insulin: new perspectives for diabetic uremic patients on CAPD. Peritoneal Dialysis Bulletin 1982; 2: 161.Google Scholar
  48. 48.
    Williams FP, Marliss EB, Anderson GH et al. Amino acids absorption following intraperitoneal administration in CAPD patients. Peritoneal Dialysis Bulletin 1982; 2: 124.Google Scholar
  49. 49.
    Twardowski ZJ, Khanna R, Nolph KD. Osmotic agents and ultrafiltration in peritoneal dialysis. Nephron 1986; 42: 93.PubMedCrossRefGoogle Scholar
  50. 50.
    Mistry CD, Mallick NP, Gokal R. The use of large molecular weight glucose polymer as an osmotic agent in CAPD. In: Khanna R, Nolph KD, Prowant BF et al. (eds), Advances in Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis Bulletin Inc, Toronto 1986; pp 7–11.Google Scholar
  51. 51.
    Matthys E, Dolkart R, Lameire N. Extended use of a glycerol containing dialysate in the treatment of diabetic CAPD patients. Peritoneal Dialysis Bulletin 1987; 7: 10.Google Scholar
  52. 52.
    Imholz ALT, Lameire N, Faict D, Koomen GCM, Krediet RT, Martis L. Evaluation of short-chain polypeptides as an osmotic agent in CAPD patients. Peritoneal Dialysis International 1993; 13: S62.Google Scholar
  53. 53.
    Goodship THJ, Heaton A, Wilkinson R, Ward MK. The use of glycerol as an osmotic agent in continuous ambulatory peritoneal dialysis. In: Ota K, Maher J, Winchester J, Hirszel P (eds), Current Concepts in Peritoneal Dialysis. Excerpta Medica, Amsterdam 1992; pp 143–47.Google Scholar
  54. 54.
    Mistry CD, Gokal R. The use of glucose polymer in CAPD: essential physiological and clinical conclusions. In: (Ota K, Maher J, Winchester J, Hirszel P (eds.) Current Concepts in Peritoneal Dialysis. Excerpta Medica, Amsterdam 1992; pp 138–42.Google Scholar
  55. 55.
    Avram MM, Paik SK, Okanya D, Rajpal K. The natural history of diabetic nephropathy: unpredictable insulin requirements. A further clue. Clin Nephrol 1984; 21: 36–8.PubMedGoogle Scholar
  56. 56.
    Duckworth WC. Insulin degradation: mechanisms, products and significance. Endocrine Rev 1988; 9: 319–45.CrossRefGoogle Scholar
  57. 57.
    Zingg W, Shirriff JM, Liebel B. Experimental routes of insulin administration. Perit Dial Bull 1982; 2: S24–7.Google Scholar
  58. 58.
    Felig P, Wahren J. The liver as site of insulin and glucagon action in normal, diabetic and obese human. Israel Journal of Medical Sciences 1975; 11: 528.PubMedGoogle Scholar
  59. 59.
    Rubin J, Reed V, Adir C, Bower J, Klein E. Effect of intraperitoneal insulin on solute kinetics in CAPD: insulin kinetics in CAPD. American Journal of Medical Sciences 1986; 291: 81.CrossRefGoogle Scholar
  60. 60.
    Rubin J, Bell AH, Andrews M, Jones Q, Planch A. Intraperitoneal insulin — a dose response curve. Transactions of American Society for Artificial Internal Organs 1989; 35: 17–21.Google Scholar
  61. 61.
    Micossi P, Crostallo M, Librenti MC, Petrella G, Galimberti G, Melandri M, Monti L, Spotti D, Scavini M, deCarlo D, Pozza G. Free-insulin profiles after intraperitoneal, intramuscular and subcutaneous insulin administration. Diabetes Care 1986; 9: 575–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Schade DS, Eaton RP. The peritoneum — a potential insulin delivery route for a mechanical pancreas. Diabetes Care 1980; 3: 229.PubMedCrossRefGoogle Scholar
  63. 63.
    Shapiro DJ, Blumenkrantz MJ, Levin SR, Coburn W. Absorption and action of insulin added to peritoneal dialysate in dogs. Nephron 1979; 23: 174.PubMedCrossRefGoogle Scholar
  64. 64.
    Wideroe T, Smeby LC, Berg KJ, Jorstad S, Svartas IM. Intraperitoneal insulin absorption during intermittent and continuous peritoneal dialysis. Kidney International 1983; 23: 22.PubMedCrossRefGoogle Scholar
  65. 65.
    Paulsen EP, Courtney JW III, Duckworth WC. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes 1979; 28: 640–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Schade DS, Duckworth WC. In search of the subcutaneous insulin degradation syndrome. N Engl J Med 1986; 315: 147–53.PubMedCrossRefGoogle Scholar
  67. 67.
    Campbell IC, Kritz H, Najemnic C, Hagmueller G, Irsigler K. Treatment of Type I diabetic with subcutaneous insulin resistance by a totally implantable insulin infusion device (Tnfusaid”). Diabetes Res 1984; 1: 83–8.PubMedGoogle Scholar
  68. 68.
    Wood DF, Goodchild K, Guillou P, Thomas DJ, Johnston DG. Management of “brittle diabetes” with a preprogrammable implanted insulin pump delivering intraperitoneal insulin. Br Med J 1990; 301: 1143–4.CrossRefGoogle Scholar
  69. 69.
    Albisser AM, Normura M, Greenberg GR, Mcphedran NT. Metabolic control in diabetic dogs treated with pancreatic autotransplants and insulin pumps. Diabetes 1986; 35: 97.PubMedCrossRefGoogle Scholar
  70. 70.
    Ishida T, Chap Z, Chou J, Lewis RM, Hartley CJ, Entman Mark L, Field JB. Effects of portal and peripheral venous insulin infusion on glucose production and utilization in depancreatized conscious dogs. Diabetes 1984; 33: 984–90.PubMedCrossRefGoogle Scholar
  71. 71.
    Kryshak EJ, Butler PD, March C, Miller A, Barr D, Polonsky K, Perkins JD, Rizza RA. Pattern of postprandial carbohydrate metabolism and effects of portal and peripheral insulin delivery. Diabetes 1990; 39: 142.PubMedCrossRefGoogle Scholar
  72. 72.
    Olefsky J. Pathogenesis of insulin resistance and hyperglycemia in non-insulin dependent diabetes mellitus. Am J Med 1985; 75: 1–7.CrossRefGoogle Scholar
  73. 73.
    DeFronzo RA. Lilly lecture 1987: the triumvirate: B-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988; 3; 667–87.Google Scholar
  74. 74.
    Campbell PJ, Mandarino LJ, Gerich JE. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin dependent diabetes mellitus. Metabolism 1988; 37: 15–21.PubMedCrossRefGoogle Scholar
  75. 75.
    Duckworth WC, Saudek CD, Henry RR. Why intraperitoneal delivery of insulin with implantable pump in NIDDM? Diabetes 1992; 41: 657–61.PubMedCrossRefGoogle Scholar
  76. 76.
    Cullen K, Steinhouse NS, Wearne KL, Welborn TA. Multiple regression analysis of risk factors for cardiovascular and cancer mortality in Busselton, Western Australia: thirteen year study. J chronic Dis 1983; 36: 371–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Heen H. Coronary-heart disease risk and impaired glucose tolerance: the White-Hall study. Lancet 1983; 1: 1372–6.Google Scholar
  78. 78.
    Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131–41.PubMedCrossRefGoogle Scholar
  79. 79.
    Shafrir E, Bergman M, Felig P. The endocrine pancreas; diabetes mellitus. In: Felig P, Baxter JD, Broadus AE, Forahman LA (eds), Endocrinology and Metabolism. McGraw-Hill Book Company, New York 1987; pp. 1043–178.Google Scholar
  80. 80.
    Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable pump. New England Journal of Medicine 1979; 300: 573.PubMedCrossRefGoogle Scholar
  81. 81.
    Selam JL, Kashyap M, Alberti KGM, Lozano J, Hanna M, Turner D, Jean-Didier N, Chan Eve, Charles MA. Comparison of intraperitoneal and subcutaneous insulin administration on lipids apolipoproteins, fuel metabolites, and hormones in Type I diabetes mellitus. Metabolism 1989; 30: 908–12.CrossRefGoogle Scholar
  82. 82.
    Kashyap ML, Gupta AK, Selam JL, Turner D, Wuceitich K, White D, Lozano J, Charles MA. Improvement in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery. (Abstract) Diabetes 1991; 40 (suppl 1): 3A.Google Scholar
  83. 83.
    Ruotolo G, Micossi P, Galimberti G, Librenti, MC, Petrella G, Marcovina S, Pozza G, Howard BV. Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in Type I diabetes. Metabolism 1990; 38: 598.CrossRefGoogle Scholar
  84. 84.
    Bagdade JD, Subbaiah PV, Ritter M, Dunn FL. Intraperitoneal insulin delivery normalizes choles-teryl ester transfer in IDDM. (Abstract) Diabetes 1991; 40 (suppl): 269A.Google Scholar
  85. 85.
    Colette C, Pares-Herbute N, Monnier L, Swlam JL, Thomas N, Mirouze J. Effect of different insulin administration modalities on vitamin D metabolism of IDDM patients. Horm Metab Res 1989; 21: 37–41.PubMedCrossRefGoogle Scholar
  86. 86.
    Saudek CD, Salem JL, Pitt HA, Waxman K, Rubio M, Jean Didier N, Turner D, Fischell RE, Charles MA. A preliminary trial of the programmable implantable medication system for insulin delivery. N Eng J Med 1989; 321: 574–9.CrossRefGoogle Scholar
  87. 87.
    Schmitz O. Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes 1985; 34: 1152–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Grefberg N, Danielson BG, Nilsson P, Berne C. Decreasing insulin requirements in CAPD patients given intraperitoneal insulin. The Journal of Diabetic Complications 1987; 1: 16–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Scalamogna A, Castelnova C, Crepaldi M, Guerra L, Graziani G, Cantaluppi A, Ponticelli C. Incidence of peritonitis in diabetic patients on CAPD: intraperitoneal vs. subcutaneous insulin therapy. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG (eds), Advances in CAPD. University of Toronto Press 1987; pp 166–70.Google Scholar
  90. 90.
    Wanless IR, Bargman JM, Oreopoulos DG, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Modern Pathol 1989; 2: 69–74.Google Scholar
  91. 91.
    Harrison NA, Rainford DJ. Intraperitoneal insulin and the malignant omentum syndrome. Nephrology Dialysis and Transplantation 1988; 3: 103.Google Scholar
  92. 92.
    Rottembourg J. Peritoneal dialysis in diabetics. In: Nolph KD (ed), Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht 1988; pp 365–79.Google Scholar
  93. 93.
    Khanna R, Oreopoulos DG. CAPD in patients with diabetes mellitus. In: Gokal R (ed), Continuous Ambulatory Peritoneal Dialysis. Churchill Livingstone, Edinburgh 1986; pp 291–305.Google Scholar
  94. 94.
    Carta Q, Monge L, Triolo G, Dani F, Salomone M, Vercellone A, Vitelli A. Continuous insulin infusion in the management of uremic diabetic patients on dialysis: clinical experience with subcutaneous and intraperitoneal delivery. Diabetic Nephropathy 1987; 4: 83–7.CrossRefGoogle Scholar
  95. 95.
    Groop LC, van Bonsdorff MC. Intraperitoneal insulin administration does not promote insulin antibody production in insulin dependent patients on dialysis. Diabetic Nephropathy 1985; 4: 80–2.Google Scholar
  96. 97.
    Henderson IS, Patterson KR, Leung ACT. Decreased intraperitoneal insulin requirements during peritonitis on continuous ambulatory peritoneal dialysis. British Medical Journal 1985; 290: 474.CrossRefGoogle Scholar
  97. 9.
    8. Rottembourg J, El Shahat Y, Agrafiotis A, Thuillier Y, de Groc F, Jacobs C, Legrain M. Continuous ambulatory peritoneal dialysis in insulin dependent diabetics: a 40 months experiment. Kidney International 1983; 23: 40.PubMedCrossRefGoogle Scholar
  98. 99.
    Nolph KD, Sorkin M, Rubin J, Arfania D, Prowant BF, Fruto L, Kennedy D. Continuous ambulatory peritoneal dialysis: three-year experience at one center. Ann Intern Med 1983; 92: 609–13.Google Scholar
  99. 100.
    Young MA, Nolph KD, Dutton S, Prowant BF. Anti-hypertensive drug requirements in continuous ambulatory peritoneal dialysis. Perit Dial Bull 1984; 5: 85–8.Google Scholar
  100. 101.
    Glasson PH, Favre H, Valloton MB. Response of blood pressure and the renin-angiotensin-aldosterone system to chronic ambulatory peritoneal dialysis in hypertensive end-stage renal failure. Clin Sci 1982; 63: S207–9.Google Scholar
  101. 102.
    Nolph KD, Hano JE, Teschan PE. Peritoneal sodium transport during hypertonic peritoneal dialysis: physiologic mechanisms and clinical implications. Ann Intern Med 1969; 70: 931–41.PubMedGoogle Scholar
  102. 103.
    Nolph KD, Sorkin M, Moore H. Autoregulation of sodium and potassium removal during continuous ambulatory peritoneal dialysis. ASAIO Trans 1980; 6: 334–7.Google Scholar
  103. 104.
    Leenen FHH, Shah P, Boer WH, Khanna R, Oreopoulos DG. Hypotension on CAPD: an approach to treatment. Perit Dial Bull 1983; 3: S33–5.Google Scholar
  104. 105.
    Rottembourg J, Issad B, Poignet JL, Stripoli P, Balducci A, Slama G, Gahl GM. Residual renal function and control of blood glucose levels in insulin-dependent diabetic patients treated by CAPD. In: Keen H, Legrain M (eds), Prevention and Treatment of Diabetic Nephropathy. MTP Press Ltd., Lancaster, Boston 1983; pp 339–359.Google Scholar
  105. 106.
    Cancarini GC, Brunori G, Camerini C, Brasa S, Manili L, Maiorca R. Renal function recovery and maintenance of residual diuresis in CAPD and hemodialysis. Perit Dial Bull 1986; 6: 77–9.Google Scholar
  106. 107.
    Lysaght M, Vonesh E, Ibels L, Lindholm B, Nolph KD, Pollock C, Prowant B, Farrell P. Decline of residual renal function in hemodialysis and CAPD patients; a risk adjusted growth function analysis. (Abstract) Nephrol Dial Transplant 1989; 4: 499.Google Scholar
  107. 108.
    Lysaght M, Pollock C, Schindaglm K, Ibeles L, Farrell P. The relevance of urea kinetic modeling to CAPD. (Abstract) ASAIO Trans 1988; 34: 84.Google Scholar
  108. 109.
    Slingeneyer A, Mion C. Five year follow-up of 155 patients treated by CAPD in European-French speaking countries. (Abstract) Perit Dial Int 1989; 7 (suppl 1): 176.Google Scholar
  109. 110.
    Rottembourg J, Issad B, Allouache M, Jacobs C. Recovery of renal function in patients treated by CAPD. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG (eds), Advances in Peritoneal Dialysis. University of Toronto Press, Toronto 1989; pp 63–6.Google Scholar
  110. 111.
    Michael C, Bindi P, Kareche M, Mignon F. Renal function on recovery on chronic dialysis: what is best, CAPD or hemodialysis? (Abstract) Nephrol Dial Transplant 1989; 4: 499–500.Google Scholar
  111. 112.
    Nunan TO, Wing AJ, Brunner FB, Seiwood NH. Native kidneys sometimes recover after prolonged dialysis and transplantation. In: Giovanetti C (ed), Proceedings of the Vth International Capri Conference on Uremia. Capri 1986; pp 132–49.Google Scholar
  112. 113.
    Nolph KD. Is residual renal failure preserved better with CAPD than hemodialysis? AKF Nephrology Letter 1990; 7: 1–4.Google Scholar
  113. 114.
    Shekkarie MA, Port FK, Wolfe RA, Guire K, Humphrys R, Van Amburg G, Gerguson CW. Recovery from end-stage renal disease. AM J Kidney Dis 1990; 15: 61–5.Google Scholar
  114. 115.
    Mourad G, Mimran A, Mion C. Recovery of renal function in patients with accelerated malignant nephrosclerosis on maintenance dialysis with management of blood pressure by captopril. Nephron 1985; 41: 166–9.PubMedCrossRefGoogle Scholar
  115. 116.
    Wauters JP, Brunner HR. Discontinuation of chronic hemodialysis after control of arterial hypertension: long-term follow-up. Proc Eur Dial Transplant Assoc 1982; 19: 182–6.Google Scholar
  116. 117.
    Herbelin A, Nguyen AT, Zingraft J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990; 37: 116–25.PubMedCrossRefGoogle Scholar
  117. 118.
    Cotran RS, Pober JS. Effects of cytokines on vascular endothelium; their role in vascular and immune injury. Kidney Int 1989; 35: 969–75.PubMedCrossRefGoogle Scholar
  118. 119.
    Shah AH. Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int 1989; 35: 1093–106.PubMedCrossRefGoogle Scholar
  119. 120.
    Rottembourg J, Bellio P, Maiga K, Remaoun M, Rousselie F, Legrain M. Visual function, blood pressure and blood glucose in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Proc Europ Dial Transpl Ass 1984; 21: 330–4.Google Scholar
  120. 121.
    Kohner E, Chahal P. Retinopathy in diabetic nephropathy. In: Prevention and Treatment of Diabetic Nephropathy. MTP Ltd, Lancaster, pp 191–196.Google Scholar
  121. 122.
    Diaz-Buxo JA, Burgess WP, Greenman M, Chandler JT, Farmer CD, Walker PJ. Visual function in diabetic patients undergoing dialysis: comparison of peritoneal and hemodialysis. Int J Artif Organs 1984; 7: 257–62.PubMedGoogle Scholar
  122. 123.
    Zimmerman SW, Johnson CA, O’Brien M. Survival of diabetic patients on continuous ambulatory peritoneal dialysis for over five years. Peritoneal Dialysis Bulletin 1987; 7: 26.Google Scholar
  123. 124.
    Dombros N Oren A, Marliss EB, Anserson GH, Stern AN, Khanna R, Pehl J, Brades L, Roddell H, Libeil BS, Oreopoulos DG. Plasma amino acids profiles and amino acid losses in patients undergoing CAPD. Perit Dial Bull 1982; 2: 37–42.Google Scholar
  124. 125.
    Norbeck H. Lipid abnormalities in continuous ambulatory peritoneal dialysis patients. In: Legrain M (ed), Continuous Ambulatory Peritoneal Dialysis. Excerpta Medica, Amsterdam 1979; pp 298–301.Google Scholar
  125. 126.
    Khanna R, Brechenridge C, Roncari D, Digenis G, Oreopoulos DG. Lipid abnormalities in patients undergoing continuous ambulatory peritoneal dialysis. Peritoneal Dialysis Bulletin 1983; 3: 13–6.Google Scholar
  126. 127.
    Gokal R, Ramos JM, McGurk JG, Ward MK, Kerr DNS. Hyperlipidemia in patient on continuous ambulatory peritoneal dialysis. In: Gahl G, Kessel M, Nolph KD (eds), Advances in Peritoneal Dialysis. Excerpta Medica, Amsterdam 1981; pp 430–3.Google Scholar
  127. 128.
    Moncrief JW, Pyle WK, Simon P, Popovich RP. Hypertriglyceridemia, diabetes mellitus and insulin administration in patient undergoing continuous ambulatory peritoneal dialysis. In: Moncrief J, Popovich R (eds), CAPD Update. Masson, New York 1981; pp 143–65.Google Scholar
  128. 129.
    Sorge F, Castro LA, Nagel A, Kessel M. Serum glucose, insulin, growth hormone, free fatty acids and lipids responses to high carbohydrate and to high fat isocaloric diets in patients with chronic, non-nephrotic renal failure. Horm Metab Res 1975; 7: 118–27.CrossRefGoogle Scholar
  129. 130.
    Sanfelippo ML, Swenson RS, Reavan GM. Response of plasma triglycerides to dietary change in patients on hemodialysis. Kidney Int 1978; 14: 180–6.PubMedCrossRefGoogle Scholar
  130. 131.
    Cattran DC, Steiner GS, Fenton SSA, Ampil M. Dialysis hyperlipemia: response to dietary manipulations. Clin Nephrol 1980; 13: 177–82.PubMedGoogle Scholar
  131. 132.
    Ramos JM, Heaton A, McGurk GJ, Ward MK, Kerr DNS. Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron 1983; 353: 20–3.CrossRefGoogle Scholar
  132. 133.
    Nolph KD, Ryan KL, Prowant B, Twardowski Z. A cross sectional assessment of serum vitamin D and triglyceride concentrations in a CAPD population. Perit Dial Bull 1984; 4: 232–37.Google Scholar
  133. 134.
    Lindholm B, Norbeck HE. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scan 1986; 220: 143–51.CrossRefGoogle Scholar
  134. 135.
    Heaton A, Johnston DG, Haigh JW, Ward MK, Alberti KGMM, Kerr DNS. Twenty-four hour hormonal and metabolic profiles in uraemic patients before and during treatment with continuous ambulatory peritoneal dialysis. Clin Sci 1985; 69: 449–57.PubMedGoogle Scholar
  135. 136.
    Keusch G, Bammatter F, Mordasini R, Binswanger U. Serum lipoprotein concentrations during continuous ambulatory peritoneal dialysis (CAPD). In: Gahl GM, Kessel M, Nolph KD (eds), Advances in Peritoneal Dialysis. Excerpta Medica, Amsterdam 1981; pp 427–9.Google Scholar
  136. 137.
    Lindholm B, Karlander SG, Norbeck HE, Fürst P, Bergström J. Carbohydrate and lipid metabolism in CAPD patients. In: Atkins R, Thomson N, Farrell P (eds), Peritoneal Dialysis. Churchill Livingstone, Edinburgh 1981; pp 198–210.Google Scholar
  137. 138.
    Lindholm B, Alvestrand A, Fürst P, Karlander SSG, Norbeck HE, Ahlberg M, Tranaeus A, Bergrström J. Metabolic effects of continuous ambulatory peritoneal dialysis. Proc EDTA 1980; 17: 283–9.Google Scholar
  138. 139.
    Lindholm B, Karlander SG, Norbeck HE, Bergström J. Glucose and lipid metabolism in peritoneal dialysis. In: La Greca G, Biasoli S, Ronco C (eds), Peritoneal Dialysis. Wichtig Editore 1982; pp 219–230.Google Scholar
  139. 140.
    Kagan A, Barkhayim Y, Schafer Z, Fainaru M. Low level of plasma HDL in CAPD patients may be due to HDL loss in dialysate. (Abstract) Peritoneal Dialysis International 1988; A: 79.Google Scholar
  140. 141.
    Roncari DAK, Breckenridge WC, Khanna R, Oreopoulos DG. Rise in high-density lipoprotein-cholesterol in some patients treated with CAPD. Perit Dial Bull 1987; 1: 136–37.Google Scholar
  141. 142.
    Breckenridge WC, Roncari DAK, Khanna R, Oreopoulos DG. The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins. Atherosclerosis 1982; 45: 249–58.PubMedCrossRefGoogle Scholar
  142. 143.
    Tuskamoto Y, Okubo M, Yoneda T, Marumo F, Nakamura H. Effects of a polyunsaturated fatty acid-rich diet on serum lipids in patients with chronic renal failure. Nephrol 1982; 31: 236–41.Google Scholar
  143. 144.
    Vas SI. Peritonitis. In: Nolph KD (ed), Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht 1989; pp 261–88.Google Scholar
  144. 145.
    Nolph KD, Cutler SJ, Steinberg SM, Novak JW. Special studies from the NIH USA CAPD Registry. Peritoneal Dialysis Bulletin 1986; 6: 28–35.Google Scholar
  145. 146.
    Rottembourg J, Brouard R, Issad B, Allouache M, Jacobs C. Prospective randomized study about Y connectors in CAPD patients. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG (eds), Advances in Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis Bulletin Inc, Toronto 1987; pp 107–13.Google Scholar
  146. 147.
    Madden MA, Zimmerman SW, Simpson DP. CAPD in diabetes mellitus — the risks and benefits of intraperitoneal insulin. (Abstract) Am J Nephrol 1982; 2: 133.CrossRefGoogle Scholar
  147. 148.
    Wing AF, Broyer M, Brunner FP, Brynger H, Challah S, Donckerwolcke RA, Gretz N, Jacobs C, Kramer P, Selwood NH. Combined report on regular dialysis and transplantation in Europe 1982. Proc Eur Dial Transplant Assoc-ERA 1983; 20: 5–75.Google Scholar
  148. 149.
    Williams C, University of Toronto Collaborative Dialysis Group. CAPD in Toronto — an overview. Peritoneal Dialysis Bulletin 1983; 35: 2.Google Scholar
  149. 150.
    U.S. Renal Data System. USRDS 1990 Annual Data Report, The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, August 1991.Google Scholar
  150. 151.
    Nelson CB, Port FK, Wolfe RA, Guire KE. Dialysis patient survival: evaluation of CAPD vs. HD using 3 techniques. (Abstract) Pent Dial Int 1992; 12 (suppl 1): 144.Google Scholar
  151. 152.
    Port KF, Held PJ, Nolph KD, Turenne MN, Wolfe RA. Risk of peritonitis and technique failure by CAPD technique: a national study. Kidney Int: (in press).Google Scholar
  152. 153.
    Keshaviah P, Nolph KD, Prowant BF, Moore H, Ponferrada L, Van Stone J, Twardowski ZJ, Khanna R. Defining adequacy of CAPD with urea kinetics. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG (eds), Advance in Peritoneal Dialysis. University of Toronto Press, Toronto 1990; pp 173–7.Google Scholar
  153. 154.
    Lameire N (Personal communication).Google Scholar
  154. 155.
    Faller B, Marichal JD. Loss of ultrafiltration in CAPD. Clinical data. In: Gahl G, Kessel M, Nolph KD (eds), Advances in Peritoneal Dialysis. Excerpta Medica, Amsterdam 1981; pp 227–32.Google Scholar
  155. 156.
    Slingeneyer A, Mion C, Mourad G, Canaud B, Faller B, Beraud JJ. Progressive sclerosing peritonitis: a late and severe complication of maintenance peritoneal dialysis. Transactions of the American Society of Artificial Internal Organs 1983; 29: 633.Google Scholar
  156. 157.
    Rottembourg J, Brouard R, Issad B, Allouache M,Ghali B, Bourjemaa A. Role of acetate in loss of ultrafiltration during CAPD. In: Berlyne GM, Giovannetti S (eds), Contribution to Nephrology. S. Karger AG, Switzerland 1987; p 197.Google Scholar
  157. 158.
    Nolph KD, Stolta M, Maher JF. Altered peritoneal permeability in patients with systematic vasculitis. Annals of Internal Medicine 1973; 78: 891.PubMedGoogle Scholar
  158. 159.
    Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, Neilsen P. Peritoneal equilibration test. Peritoneal Dialysis Bulletin 1987; 7: 138.Google Scholar
  159. 160.
    Hallett MD, Kush RD, Lysaght MJ, Farrell PC. The stability and kinetics of peritoneal mass transfer. In: Nolph KD (ed), Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht 1989; pp 380–8.CrossRefGoogle Scholar
  160. 161.
    Struijk DG, Krediet RT, Koomen GCM, Hoek FJ, Boeschoten EW, Reijden HJ, Arisz L. Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 213–20.PubMedCrossRefGoogle Scholar
  161. 162.
    Gilmore J, Wu G, Khanna R, Oreopoulos DG. Long term CAPD. Peritoneal Dialysis Bulletin 1985; 5: 112.Google Scholar
  162. 163.
    Peters C, Sutherland D, Simmon R, Fryd DS, Najarian JS. Patients and graft survival in amputated vs non-amputated diabetic primary renal allograft recipients. Transplantation 1981; 32: 498–503.PubMedCrossRefGoogle Scholar
  163. 164.
    Joint Working Party. Renal failure in diabetes in UK: deficient provision of care in 1985. Diabetic Med 1988; 5: 79–84.CrossRefGoogle Scholar
  164. 165.
    Bailey TS, Yu H, Royfield E. Patterns of test examination in a Diabetic clinic. Am J Med 1985; 78: 371–4.PubMedCrossRefGoogle Scholar
  165. 166.
    Thomson FJ, Veves A, Ashe H et al. A team approach to diabetes foot-care — the Manchester experience. The Foot 1991; 2: 75–82.CrossRefGoogle Scholar
  166. 167.
    Fernando D, Hutchison A, Veves A, Gokal R, Boulton A. Risk factors for non-ischaemic foot ulceration in Diabetic Nephropathy. Diabetic Med 1991; 8; 1–4.CrossRefGoogle Scholar
  167. 168.
    Boulton AJM, Gokal R, Marion EA. The formation of a diabetic nephropathy clinic. Report of the first six months. Postgrad Med J 1988; 64: 84–6.Google Scholar
  168. 169.
    Mistry CD, Gokal R, Peers E, MIDAS Study Group. Multicentre trial of Dextrin 20 in CAPD patients. Kidney Int: 1994 (in press).Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1994

Authors and Affiliations

  • Ramesh Khanna

There are no affiliations available

Personalised recommendations